Tagged with P

Japan Osamu Nagayama, president of the Japan BioIndustry Association (JBA) and chairman and CEO of Chugai Pharmaceutical, discusses Japan’s footprint in biologics and how mergers between Japanese pharma companies, thereby creating larger R&D funding pools, could hold the key to future success in the biotechnology field. Can you begin by introducing…

Poland Maciej Kuźmierkiewicz, general manager of IQVIA Poland and the Baltics, discusses the implications of global changes on the Polish affiliate (which now employs 1000 staff) and the challenges of promoting an abundance of services to the marketplace. Additionally, he highlights the potential of healthcare services in Poland to deliver clinical…

Poland Wojciech Koziejowski, managing director of Lundbeck Poland, discusses attaining reimbursement in Poland for the first time in ten years and the recent set-up of their global shared service center of more than 200 staff in Krakow. Moreover, he highlights the leading role the company is taking in educating key stakeholders…

Lithuania Darius Sinkevičius, chairman of the board at the Lithuanian Association of Generic Pharmaceuticals Manufacturers (VGA), explains the main trends impacting the generic pharmaceutical industry in the country as well as the role of off-patent medicines in creating savings for the Lithuanian healthcare system. Can you give to our international audience…

Brazil Fraser Hall, country president of AstraZeneca Brazil, describes the current trends and dynamics shaping the Brazilian pharmaceutical market and documents the promising partnership opportunities he envisions to significantly increase patient access in both the private and public sectors. You were appointed country president of AstraZeneca Brazil in September 2016 after…

Poland Denis Vujičić, managing director of MSD Poland, discusses his overriding mission to give Polish patients greater access to breakthrough therapies and highlights the affiliate’s extensive R&D capabilities that entail both domestic and global operations. Furthermore, he highlights the important steps that MSD is undertaking to strengthen its position as the…

Canada John London, CEO at Nuvo Pharmaceuticals Inc., explains how he and his partners turned the Canadian company from insolvency into a profitable enterprise with FDA approved products that are being marketed around the world. He further talks opportunities in the topical pain management market and how Nuvo Pharmaceuticals will enhance…

Brazil Sameer Savkur, country manager of Biogen Brazil, provides insights into the key specificities of the Brazilian pharmaceutical ecosystem and documents the great successes of Biogen affiliate in working hand-in-hand with all key public and regulatory stakeholders in Brazil, as recently illustrated with Biogen’s innovative treatment for spinal muscular atrophy (SMA),…

Switzerland In an exclusive interview, Bruno Strigini, global CEO of Novartis Oncology, discusses the logic of the company’s separate oncology business unit, the significance of US FDA approval for the new CAR-T cell therapy, Kymriah, and the issues around pricing for this revolutionary treatment.   * Please note that this interview was…

India “From illness to wellness” – this is what Apollo Life is all about. Ariz Rizvi, president of Apollo Life, gives his insight into the current state of occupational and rehabilitative health in India and explains how the company has revolutionized wellness in workplaces over the past years. Mr. Rizvi, you…

Brazil Henrique Tada, executive director of ALANAC, the association gathering Brazilian pharmaceutical companies, provides an historical overview of the rapid and eye-catching growth of the local pharmaceutical industry and documents the new development opportunities envisioned by domestic manufacturers with regards to botanical and biological drugs as well as their competitive advantages…

Austria Alexander Biach, chairman of the Main Association of Austrian Social Security Institutions, discusses handling the responsibility for Austria’s Europe-leading social security coverage, current inefficiencies that need to be ironed out, and his blueprint for creating a faster, less complicated, more cost-effective, and equitable social insurance system. Last May, you were…